AdCOVID™

Single-Dose Intranasal COVID-19 Vaccine

coronavirus COVID-19A single-dose, intranasal vaccine candidate designed to protect against COVID-19, the disease caused by the SARS-CoV-2 virus. By utilizing the Company’s proprietary intranasal vaccine technology, it is expected that AdCOVID has the potential to activate multiple arms of the immune system as shown in a recent Phase 2 clinical study with NasoVAX, an influenza vaccine candidate based on the same platform technology. That study showed potent stimulation of mucosal and cellular immune responses in addition to a strong serum antibody response.

In addition, our platform vaccines (NasoVAX and NasoShield) have shown an excellent stability profile and, when combined with the simple intranasal route of administration, may allow for efficient and inexpensive distribution of the vaccine.